Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00404521 · ClinicalTrials.gov registry record · Phase 1
A Phase I Study of PM02734 in Subjects With Advanced Malignant Solid Tumors
A Phase 1 study, sponsored by PharmaMar.
- Terminated
- Registry status
- Phase 1
- Development phase
- 56
- Enrollment target
NCT00404521 is a Phase 1 study that was terminated before completion, run by PharmaMar. The registered enrollment target is 56 participants.
The verdict
NCT00404521, a Phase 1 study, was terminated before completion, sponsored by PharmaMar.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 56 participants
- Enrollment target
Study Summary
Phase I single-institution, open-label, dose-escalating, clinical and pharmacokinetic study. The purpose is to determine the safety, tolerability and to identify the dose limiting toxicities(DLT) and recommended dose (RD) of PM02734 administered every 3 weeks, intravenously, over 30 minutes to subjects with advanced malignant solid tumors.
Interventions
- DRUG PM02734
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2005-08 |
| Est. Completion | 2011-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00404521
The ClinicalTrials.gov registry entry for NCT00404521 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is PharmaMar, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PM02734 is the first listed.
NCT00404521 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00404521 about?
NCT00404521 is a clinical study titled "A Phase I Study of PM02734 in Subjects With Advanced Malignant Solid Tumors". Phase I single-institution, open-label, dose-escalating, clinical and pharmacokinetic study. The purpose is to determine the safety, tolerability and to identify the dose limiting toxicities(DLT) and recommended dose (RD) of PM02734 administered every 3 weeks, intravenously, over 30 minutes to subje...
What is the current status of trial NCT00404521?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2005-08. Estimated completion is 2011-05.
What interventions are being tested in trial NCT00404521?
The interventions under investigation include: PM02734 (DRUG).
Who is sponsoring clinical trial NCT00404521?
This trial is sponsored by PharmaMar, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.